Prostamax
Prostate bioregulator peptide
Prostate tissue bioregulator.
Half-life
~ hours
Mol. weight
~ 444.5 g/mol
Sequence
Lys-Glu-Asp-Pro (KEDP)
Discussions
0 threads
Overview
A short bioregulator peptide studied for regulating gene expression in prostate tissue, with proposed support for prostate cell function. It applies the Khavinson bioregulator framework to the prostate — a gland of significant clinical importance given the prevalence of benign and malignant prostate conditions with age.
Mechanism of action
Prostamax is a bioregulator peptide studied for regulating gene expression in prostate tissue. The prostate is a clinically significant gland: benign prostatic hyperplasia is near-universal with aging, and prostate cancer is among the most common male malignancies. Prostamax applies the Khavinson ultra-short-peptide framework to that target, conceptually aiming at prostate cell gene expression. As with all bioregulators, the evidence base is concentrated in one research tradition.
Researched benefits
- Studied for prostate tissue support
- Targets a clinically important gland
- Short bioregulator format
Considerations
- Prostate conditions require medical diagnosis and care
- Evidence concentrated in one tradition
- Human data limited
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating Prostamax in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on Prostamax:
View Prostamax index on PubMed (NCBI)